U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Safety
  3. Recalls, Market Withdrawals, & Safety Alerts
  4. Baxter Issues Urgent Medical Device Correction for Spectrum V8 and Spectrum IQ Infusion Pumps with Specific Software Versions
  1. Recalls, Market Withdrawals, & Safety Alerts

COMPANY ANNOUNCEMENT

Baxter Issues Urgent Medical Device Correction for Spectrum V8 and Spectrum IQ Infusion Pumps with Specific Software Versions

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

Read Announcement

Summary

Company Announcement Date:
FDA Publish Date:
Product Type:
Medical Devices
Reason for Announcement:
Recall Reason Description
Due to an increase in reported false upstream occlusion alarms following the software upgrades.
Company Name:
Baxter International Inc.
Brand Name:
Brand Name(s)
SIGMA Spectrum and Spectrum IQ
Product Description:
Product Description
Infusion pumps

Company Announcement

DEERFIELD, Ill., July 28, 2023 – Baxter International Inc. announced today it has issued an Urgent Medical Device Correction for Spectrum V8 and Spectrum IQ infusion pumps in the U.S. and Puerto Rico that have been upgraded to software versions v8.01.01 and v9.02.01. The Correction is due to an increase in reported false upstream occlusion alarms following the software upgrades. Baxter will be working with customers to revert the software on all affected pumps to the previous software version.

The upgraded software installed on Spectrum V8 and Spectrum IQ infusion pumps may cause an alarm for an upstream occlusion when there is no actual upstream occlusion present. This false alarm may lead to an interruption or delay of therapy. An interruption or delay of therapy may cause serious adverse health consequences in patients who are receiving life-sustaining medications. Baxter has received three reports of serious injury potentially associated with this issue.

Baxter representatives are contacting all affected customers to schedule the software reversion. Until the reversion is completed, false upstream occlusion alarms can occur on impacted pumps at a higher rate. Customers can continue to use Spectrum V8 and Spectrum IQ infusion pumps by following on-screen instructions or referencing the Preparing the Pump and IV Sets and Programming the Pump sections and upstream occlusion alarm troubleshooting in the Alarms section of the Operator’s Manual. If a customer is unable to resolve an upstream occlusion alarm, they should unload and reload the set.

This Urgent Medical Device Correction applies to SIGMA Spectrum Infusion System (V8 Platform) with product code 35700BAX2 and software version v8.01.01 and Spectrum IQ Infusion System with Dose IQ Safety Software with product code 3570009 and software version v9.02.01.

Spectrum V8 and Spectrum IQ infusion pumps are distributed in the United States, Puerto Rico, Canada and certain Caribbean islands. Only customers in the U.S. and Puerto Rico are affected by this Correction. Customers with additional questions can contact their Baxter sales representative, or Baxter Technical Assistance at 800-356-3454 (choose option 3) Monday through Friday between 6 a.m. and 6 p.m. Central Time. Any adverse events experienced with the use of these products may be reported using one of the following options:

Baxter is voluntarily issuing this Urgent Medical Device Correction with the knowledge of the U.S. Food and Drug Administration.

About Baxter
Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Media Contact
Bess Featherstone, (224) 948-5353
media@baxter.com

Investor Contact
Clare Trachtman, (224) 948-3020

###

Company Contact Information

Consumers:
Baxter Technical Assistance
800-356-3454
Media:
Bess Featherstone
224-948-5353
media@baxter.com
Back to Top